Triazole derivatives as potential xanthine oxidase inhibitors: Design, enzyme inhibition potential, and docking studies.
- Published in:
- Archiv der Pharmazie, 2024, v. 357, n. 4, p. 1, doi. 10.1002/ardp.202300296
- By:
- Publication type:
- Article
Works by Bhagat, Kavita
Results: 7
1
2
Design, synthesis, and biological evaluation of isatin‐indole‐3‐carboxaldehyde hybrids as a new class of xanthine oxidase inhibitors.
- Published in:
- Archiv der Pharmazie, 2022, v. 355, n. 6, p. 1, doi. 10.1002/ardp.202200033
- By:
- Publication type:
- Article
3
Shikonin derivatives as potent xanthine oxidase inhibitors: in-vitro study.
- Published in:
- Natural Product Research, 2023, v. 37, n. 16, p. 2795, doi. 10.1080/14786419.2022.2132499
- By:
- Publication type:
- Article
4
Discovery of potent inhibitors for M<sup>pro</sup> enzyme of SARS-COV2 by multi-stage in-silico screening of Alkannin/shikonin.
- Published in:
- Natural Product Research, 2022, v. 36, n. 18, p. 4804, doi. 10.1080/14786419.2021.2013212
- By:
- Publication type:
- Article
5
Most recent strategies targeting estrogen receptor alpha for the treatment of breast cancer.
- Published in:
- Molecular Diversity, 2021, v. 25, n. 1, p. 603, doi. 10.1007/s11030-020-10133-y
- By:
- Publication type:
- Article
6
Rational approaches for the design of various GABA modulators and their clinical progression.
- Published in:
- Molecular Diversity, 2021, v. 25, n. 1, p. 551, doi. 10.1007/s11030-020-10068-4
- By:
- Publication type:
- Article
7
Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021).
- Published in:
- Expert Opinion on Therapeutic Patents, 2022, v. 32, n. 10, p. 1079, doi. 10.1080/13543776.2022.2130752
- By:
- Publication type:
- Article